At the British International School of Boston, we offer your child a distinctly different education of the highest academic quality. BISB goes beyond traditional education to transform learning. We provide students, toddlers through high school, with opportunities and experiences that they cannot get anywhere else. As a member of Nord Anglia Education, a global family of premium schools, BISB provides students with enriched curricula through collaborations with the Massachusetts Institute of Technology (MIT), The Juilliard School, and UNICEF. Your child will discover worldwide learning opportunities through their Global Campus activities, from expeditions in Tanzania and Switzerland, to summer programs and international sports competitions. BISB provides individualized education for each student, challenging them to be ambitious. The high school culminates in the prestigious International Baccalaureate Diploma Programme (IBDP), allowing students to stand out to top-tier universities in the United States and internationally as the best of the best.
As pioneers in neuroscience, Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to address a defining pathology of Alzheimer’s disease. Biogen is also commercializing biosimilars and focusing on advancing one of the industry’s most diversified pipelines in neuroscience that will transform the standard of care for patients in several areas of high unmet need.
The Biogen Foundation
The Biogen Foundation supports access to science education and to essential human services for children and their families in the communities in which Biogen facilities are located. The Biogen Foundation is committed to sparking a passion for science and discovery, supporting effective science education initiatives and strengthening efforts to make science education and science careers accessible to diverse populations.
Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments and guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology. Takeda makes targeted R&D investments in Plasma-Derived Therapies and vaccines. Takeda focuses on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.
A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies and has reached millions of patients around the world. Amgen is a values-based organization, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illness. Amgen’s belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We have the brightest people in the industry and believe that their diverse experiences and perspectives help to bring out our best ideas, drive innovation and achieve transformative results. Each day, our employees around the world work together for patients: patients are at the center of everything we do. They inspire us. They are the reason we come to work each day.
FUJIFILM Diosynth Biotechnologies is a Contract Development and Manufacturing Organization (CDMO) partner for life. FUJIFILM Diosynth’s focus is to combine technical leadership in cell culture, microbial fermentation, and cell and gene therapy with world class cGMP manufacturing facilities to advance tomorrow’s medicines.
Millipore Sigma’s purpose is to impact life and health with science. We offer one of the broadest portfolios in the industry for scientists, best-in-class products for pharmaceutical development and manufacturing, and a fully integrated service organization to support CDMO and contract testing across traditional and novel modalities. Our vision is a world where our innovative products, services, and digital offerings help create solutions for people globally and a sustainable future for generations to come.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of health care products including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.
At Philips, our purpose is to improve people’s health and well-being through meaningful innovation. Philips aims to improve 2.5 billion lives per year by 2030, including 400 million in underserved communities. As a technology company, we – and our brand licensees – innovate for people with one consistent belief: there’s always a way to make life better.
Siena Construction is a full-service construction management firm specializing in renovations for the life sciences, commercial, retail, academic, and non-profit sectors throughout greater Boston. A Cambridge-based firm since its founding in 1991, Siena’s team has a depth of building experience and proven track record of success, creating vibrant, dynamic spaces bursting with character and culture. Their work ranges from historic town squares to state-of-the-art medical institutions that bring people together, enrich health, and inspire creative talent.
Integrating energy-efficient designs and development can reduce long-term environmental impacts, provide owners with energy cost savings, and create efficient spaces to live and work. In 2020, Siena partnered with MIT Sloan School Laboratory for Sustainable Business (S-Lab) to study construction’s environmental impacts, and reduce non-recyclable materials on construction jobs. S-Lab students performed a material life cycle analysis, identifying opportunities for material reuse, allowing Siena and others to take a proactive approach to sustainable measures.
“Bucky” popularized the design of the geodesic dome, a self-supporting structure that could be constructed with minimal materials for a wide variety of uses, from farming to dwelling. His theory of “Spaceship Earth” encourages and inspires people to work harmoniously and for the greater good of the planet and all its inhabitants – ecology and living beings.
At Thermo Fisher Scientific, everything we do is driven by our Mission to enable our customers to make the world healthier, cleaner, and safer. It is our purpose—the heart of who we are as a Company—and it inspires our more than 100,000 colleagues to bring their best every day. Our global team helps our customers discover new therapies and medicines, protect the environment, make sure our food is safe and advance science through thousands of other bold projects that improve millions of lives.
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an innovative, entirely new class of medicines. Founded in 2002 by a team of distinguished life sciences leaders, Alnylam’s vision is to harness the potential of RNAi therapeutics to transform the lives of people living with diseases for which there are limited or inadequate treatment options. Alnylam is advancing a deep pipeline of innovative RNAi-based medicines in four therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases.
Founded in 1993, DivcoWest is a vertically integrated, real estate investment firm headquartered in San Francisco, with offices in Cambridge, Los Angeles, Menlo Park, Washington DC, and New York City. Known for long-standing relationships and experience across the risk-spectrum in innovation markets, DivcoWest combines entrepreneurial spirit with an institutional approach to commercial real estate. DivcoWest aims to create environments that inspire ingenuity, promote growth, and enhance health and well-being. Since inception, DivcoWest and its predecessor have acquired approximately 58 million square feet of commercial space – primarily throughout the United States. DivcoWest’s real estate portfolio currently includes existing and development properties in the office, R&D, lab, industrial, retail, and multifamily spaces.